Welcome to our dedicated page for BIOGEN SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
BIOGEN INC ownership filing: FMR LLC reports beneficial ownership of 12,807,541.50 shares of Common Stock, representing 8.7% of the class as of 03/31/2026. The filing is an amendment (Schedule 13G/A) naming Abigail P. Johnson in a related disclosure and references an exhibit identifying the acquiring subsidiary and a power of attorney.
BIOGEN INC. Head of Corporate Development Adam Keeney reported routine equity compensation transactions involving the company’s common stock. On May 1, 2026, 939 restricted stock units were exercised into 939 shares of common stock at a conversion price of $0.00 per share. To cover tax obligations, 455 shares of common stock were disposed of at a price of $187.06 per share as a tax-withholding transaction, not an open-market sale. Following these transactions, Keeney directly owned 6,365 shares of Biogen common stock. The restricted stock units that were exercised were part of an award that vests in three equal yearly installments beginning on the first anniversary of the May 1, 2023 grant date.
Biogen Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 10,989,562 shares of Biogen common stock, representing 7.48% of the class. The filing shows Vanguard has sole voting power for 1,452,145 shares and sole dispositive power for 10,989,562 shares.
The Schedule 13G statement describes holdings across Vanguard business units and notes the reported interests include shares held for Vanguard funds and other managed accounts.
Biogen Inc. reported modestly higher quarterly revenue and stronger profits while outlining a sizable acquisition. For the three months ended March 31, 2026, revenue rose to $2.48 billion from $2.43 billion a year earlier, driven by multiple sclerosis, rare disease and anti-CD20 program revenue.
Net income attributable to Biogen increased to $319.5 million, up from $240.5 million, with diluted EPS improving to $2.15 from $1.64. Operating cash flow strengthened to $645.5 million, supporting a cash and cash equivalents balance of $3.38 billion and total assets of $29.48 billion.
Biogen also agreed to acquire Apellis Pharmaceuticals for $41.00 per share in cash, valuing the deal at about $5.6 billion, plus a contingent value right of up to $4.00 per share tied to SYFOVRE sales. The company plans to fund the purchase with roughly $3.6 billion of existing cash and marketable securities and about $2.0 billion in bank loans, aiming to add two approved immunology and rare disease products to its portfolio.
Biogen Inc. reported first quarter 2026 revenue of $2.48 billion, up 2% year-over-year, with GAAP diluted EPS of $2.15 (up 31%) and Non-GAAP diluted EPS of $3.57 (up 18%). Growth products collectively grew 12% year-over-year, led by LEQEMBI in‑market sales of $168 million, SKYCLARYS at $151 million, ZURZUVAE at $55 million, VUMERITY at $179 million, SPINRAZA at $374 million, and QALSODY at $33 million.
Biogen highlighted new positive data from late-stage programs, including litifilimab in cutaneous lupus and additional salanersen data in SMA, as well as strong LEQEMBI persistence and U.S. approval of the SPINRAZA High Dose Regimen. The company announced a proposed acquisition of Apellis Pharmaceuticals, expected to be accretive in 2027 and to materially increase Biogen’s Non-GAAP diluted EPS compounded annual growth rate through the end of the decade. Biogen also signed an agreement with TJ Biopharma for exclusive felzartamab rights in Greater China.
For full year 2026, Biogen now expects Non-GAAP diluted EPS between $14.25 and $15.25, excluding any Apellis impact, and anticipates total revenue will decline by a mid-single digit percentage versus 2025. The EPS outlook includes about $1.00 of acquired IPR&D charges tied to ongoing business development. Q1 2026 free cash flow was $594.3 million, and cash and cash equivalents were $3.38 billion as of March 31, 2026.
Biogen Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 9, 2026. Proposals include electing 10 directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and an advisory vote on executive pay.
The proxy highlights a late-stage pipeline and notes a 2026 merger agreement with Apellis Pharmaceuticals, expected to add EMPAVELI and SYFOVRE and expand into nephrology and retinal diseases. Biogen outlines extensive board refreshment, with most independent directors appointed since 2019 and an independent chair structure transitioning to Dr. Maria C. Freire.
Executive compensation changes respond to 67.7% Say on Pay support in 2025, adding caps when revenue and EPS underperform, introducing a pipeline metric to performance stock units, raising the rTSR target to the 55th percentile, and tightening CEO bonus alignment to company results. The proxy also details corporate responsibility efforts, including more than $34.6 million in 2025 community contributions and progress on emissions and waste reduction.
Biogen Inc. disclosed that its first-quarter 2026 results will include approximately $34 million in acquired in-process research and development, upfront and milestone expense on a pre-tax basis. This charge is expected to reduce GAAP and non-GAAP net income by about $0.19 per diluted share for the quarter ended March 31, 2026.
These expenses relate to collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of in-process R&D. Biogen noted that quarterly results are preliminary and subject to closing procedures, and actual results may differ from current estimates.
BIOGEN INC. Chief Accounting Officer Sean Godbout exercised 181 restricted stock units into 181 shares of common stock on April 1, 2026. The RSUs, granted on April 1, 2025, vest in three equal yearly installments, and this transaction reflects one vesting event.
To cover tax obligations, 54 shares of common stock were withheld at a price of $183.78 per share, leaving a net increase of 127 shares. Following these compensation-related transactions, Godbout directly holds about 1,341.6667 shares of Biogen common stock, indicating a routine equity vesting and tax-withholding pattern rather than open-market trading.
Biogen Inc. is buying Apellis Pharmaceuticals through a cash tender offer plus contingent value rights to expand its immunology and rare disease portfolio. Biogen will offer $41.00 in cash per Apellis share, valuing the upfront deal at approximately $5.6 billion.
Apellis stockholders will also receive one non‑transferable contingent value right per share, with potential additional cash payments of up to $4.00 per share tied to future global net sales milestones for SYFOVRE. The boards of both companies unanimously approved the merger, which uses a tender offer followed by a Section 251(h) Delaware merger and includes standard regulatory and minimum tender conditions.